Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AGIO
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.28 billion
  • Outstanding Shares: 48,204,000
Average Prices:
  • 50 Day Moving Avg: $51.01
  • 200 Day Moving Avg: $50.50
  • 52 Week Range: $35.84 - $67.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.25
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $49.12 million
  • Price / Sales: 46.36
  • Book Value: $7.25 per share
  • Price / Book: 6.52
  • EBIDTA: ($238,380,000.00)
  • Net Margins: -341.56%
  • Return on Equity: -53.39%
  • Return on Assets: -35.70%
  • Current Ratio: 7.70%
  • Quick Ratio: 7.70%
  • Average Volume: 591,369 shs.
  • Beta: 1.97
  • Short Ratio: 13.19

Frequently Asked Questions for Agios Pharmaceuticals (NASDAQ:AGIO)

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) released its quarterly earnings results on Thursday, May, 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.24. The business had revenue of $10.51 million for the quarter, compared to the consensus estimate of $9.65 million. Agios Pharmaceuticals had a negative net margin of 341.56% and a negative return on equity of 53.39%. The business's revenue was down 66.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.64) EPS. View Agios Pharmaceuticals' Earnings History.

When will Agios Pharmaceuticals make its next earnings announcement?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Agios Pharmaceuticals.

Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2017?

12 brokerages have issued 12 month price targets for Agios Pharmaceuticals' shares. Their forecasts range from $45.00 to $90.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $62.78 in the next twelve months. View Analyst Ratings for Agios Pharmaceuticals.

What are analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Agios's shares have outperformed the Medical-Products industry so far this year. As a development-stage company, Agios depends heavily on Celgene for revenues. However, the collaboration with Celgene is encouraging as it provides Agios funds in the form of upfront, regulatory and commercial milestone payments plus royalties. In terms of the company’s pipeline, most of the candidates are in mid and early stages of development and thus, several years away from entering the market. Moreover, the decision to discontinue the development of AG-519 is disappointing. Stiff competition is another matter of concern for the company. Estimates have been going down lately ahead of the company’s Q1 earnings release. The company has mixed record of earnings surprises in recent quarters." (4/28/2017)
  • 2. Cann analysts commented, "Agios Pharmaceuticals announced today that it priced an offering of 5,050,505 shares of common stock at a price to the public of $49.50 per share, before underwriting discounts. All of the shares in the offering are to be sold by Agios. Agios has also granted the underwriters a 30-day option to purchase from it up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions." (4/19/2017)
  • 3. Cowen and Company analysts commented, "Agios ended 2016 with $574MM in cash, enough to last through 2018." (2/16/2017)
  • 4. Credit Suisse Group AG analysts commented, "We view this as positive proof of concept for the inhibition of mutIDH in the treatment of IDHmut glioma. We note AG-120 shows only limited brain penetration, and we view these data providing a positive read-through for AG-881’s development in this indication." (11/21/2016)

Who are some of Agios Pharmaceuticals' key competitors?

Who owns Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (0.00%), Wellington Management Group LLP (0.00%), CELGENE EUROPEAN INVESTMENT COMPANY LLC (12.40%), BB Biotech AG (0.00%), Vanguard Group Inc. (0.00%) and BlackRock Inc. (0.00%). Company insiders that own Agios Pharmaceuticals stock include Celgene European Investment Co, Christopher Bowden, David P Schenkein, Glenn Goddard, John Duncan Higgons, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Institutional Ownership Trends for Agios Pharmaceuticals.

Who sold Agios Pharmaceuticals stock? Who is selling Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Point72 Asset Management L.P., State Street Corp, Oxford Asset Management, Columbia Wanger Asset Management LLC, Morgan Stanley, Spark Investment Management LLC and State of Wisconsin Investment Board. Company insiders that have sold Agios Pharmaceuticals stock in the last year include David P Schenkein, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Insider Buying and Selling for Agios Pharmaceuticals.

Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Redmile Group LLC, Vanguard Group Inc., First Trust Advisors LP, Capital Fund Management S.A., Quantitative Investment Management LLC and Credit Suisse AG. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy Agios Pharmaceuticals stock?

Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Agios Pharmaceuticals stock cost?

One share of Agios Pharmaceuticals stock can currently be purchased for approximately $47.24.

Analyst Ratings

Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (?)
Ratings Breakdown: 3 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $62.78 (32.89% upside)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Canaccord GenuitySet Price TargetBuy$90.00MediumView Rating Details
4/19/2017CannReiterated RatingBuy$75.00HighView Rating Details
4/18/2017Credit Suisse Group AGReiterated RatingOutperform$61.00HighView Rating Details
3/1/2017Oppenheimer Holdings Inc.Set Price TargetBuy$75.00N/AView Rating Details
2/16/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
2/16/2017Janney Montgomery ScottUpgradeNeutral -> Buy$57.00N/AView Rating Details
1/17/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
12/19/2016Leerink SwannReiterated RatingMarket Perform$56.00 -> $45.00N/AView Rating Details
12/16/2016Needham & Company LLCReiterated RatingBuy$60.00 -> $54.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageNeutralN/AView Rating Details
8/10/2016Goldman Sachs Group IncReiterated RatingNeutral$46.00N/AView Rating Details
6/13/2016JPMorgan Chase & Co.UpgradeNeutral -> Overweight$50.00 -> $62.00N/AView Rating Details
5/18/2016SunTrust Banks, Inc.Boost Price TargetBuy$57.00 -> $65.00N/AView Rating Details
11/9/2015Roth CapitalLower Price TargetNeutral$114.00 -> $75.00N/AView Rating Details
7/22/2015Northland SecuritiesInitiated CoverageOutperform$132.00N/AView Rating Details
7/2/2015DesjardinsUpgradeHold -> BuyN/AView Rating Details
6/2/2015Citigroup IncInitiated CoverageNeutral$132.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)
Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Earnings History by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($1.80)($1.56)$9.65 million$10.51 millionViewListenView Earnings Details
2/16/2017Q416($1.51)($1.34)$10.89 million$22.65 millionViewListenView Earnings Details
11/3/2016Q316($1.52)($1.63)$7.82 million$8.98 millionViewListenView Earnings Details
8/4/2016Q216($0.48)($1.47)$39.62 million$6.98 millionViewListenView Earnings Details
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details
2/18/2016Q415($0.27)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details
5/7/2015Q115($0.86)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details
2/17/2015Q414($0.55)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details
11/7/2014Q314($0.53)$0.10$8.45 million$33.90 millionViewListenView Earnings Details
8/7/2014Q2($0.47)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details
5/8/2014Q1($0.37)($0.39)$7.19 million$8.41 millionViewListenView Earnings Details
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details
11/7/2013($0.28)($0.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)
2017 EPS Consensus Estimate: ($7.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.86)($1.78)($1.81)
Q2 20173($1.92)($1.80)($1.88)
Q3 20172($1.98)($1.96)($1.97)
Q4 20171($1.95)($1.95)($1.95)
(Data provided by Zacks Investment Research)


Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Agios Pharmaceuticals (NASDAQ:AGIO)
Insider Ownership Percentage: 10.55%
Institutional Ownership Percentage: 88.79%
Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/1/2017David P SchenkeinCEOSell3,000$50.06$150,180.00View SEC Filing  
4/24/2017Celgene European Investment CoMajor ShareholderBuy624,575$49.50$30,916,462.50View SEC Filing  
4/18/2017Lewis Clayton Jr. CantleyDirectorSell5,090$54.37$276,743.30View SEC Filing  
4/17/2017Lewis Clayton Jr. CantleyDirectorSell2,036$55.24$112,468.64View SEC Filing  
4/3/2017David P SchenkeinCEOSell3,000$58.62$175,860.00View SEC Filing  
4/3/2017Scott BillerInsiderSell2,146$58.03$124,532.38View SEC Filing  
3/23/2017Lewis Clayton Jr. CantleyDirectorSell2,036$53.11$108,131.96View SEC Filing  
3/20/2017Scott BillerInsiderSell6,438$55.00$354,090.00View SEC Filing  
3/6/2017Robert NelsenDirectorSell40,599$50.84$2,064,053.16View SEC Filing  
2/28/2017Robert NelsenDirectorSell243,082$49.36$11,998,527.52View SEC Filing  
2/23/2017Robert NelsenDirectorSell135,364$49.37$6,682,920.68View SEC Filing  
2/16/2017David P SchenkeinCEOSell6,000$50.01$300,060.00View SEC Filing  
10/27/2016Lewis Clayton Jr. CantleyDirectorSell2,504$48.94$122,545.76View SEC Filing  
10/5/2016Scott BillerInsiderSell5,000$55.00$275,000.00View SEC Filing  
9/28/2016Lewis Clayton Jr. CantleyDirectorSell627$54.00$33,858.00View SEC Filing  
9/27/2016Lewis Clayton Jr. CantleyDirectorSell627$54.15$33,952.05View SEC Filing  
9/20/2016Scott BillerInsiderSell5,000$50.00$250,000.00View SEC Filing  
8/30/2016Lewis Clayton Jr. CantleyDirectorSell627$36.81$23,079.87View SEC Filing  
8/29/2016Lewis Clayton Jr. CantleyDirectorSell627$37.81$23,706.87View SEC Filing  
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20View SEC Filing  
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95View SEC Filing  
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52View SEC Filing  
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99View SEC Filing  
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.00View SEC Filing  
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76View SEC Filing  
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76View SEC Filing  
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00View SEC Filing  
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76View SEC Filing  
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60View SEC Filing  
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72View SEC Filing  
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52View SEC Filing  
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.00View SEC Filing  
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64View SEC Filing  
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.00View SEC Filing  
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.00View SEC Filing  
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64View SEC Filing  
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.00View SEC Filing  
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.00View SEC Filing  
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00View SEC Filing  
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00View SEC Filing  
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00View SEC Filing  
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00View SEC Filing  
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00View SEC Filing  
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.00View SEC Filing  
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.00View SEC Filing  
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00View SEC Filing  
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00View SEC Filing  
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.00View SEC Filing  
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86View SEC Filing  
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00View SEC Filing  
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Agios Pharmaceuticals (NASDAQ:AGIO)
Latest Headlines for Agios Pharmaceuticals (NASDAQ:AGIO)
DateHeadline logoDrugmakers increasingly view Trump as a business risk in federal filings - May 24 at 3:24 PM logoETFs with exposure to Agios Pharmaceuticals, Inc. : May 22, 2017 - May 22 at 3:24 PM
News IconAgios Pharmaceuticals and cancer cell metabolism - Business Insider - Business Insider - May 22 at 6:25 AM logoA small Boston biotech is at the heart of a groundbreaking approach to tackling cancer - May 21 at 3:23 PM logoCanaccord Genuity Analysts Give Agios Pharmaceuticals Inc (AGIO) a $90.00 Price Target - May 19 at 5:54 PM logoAgios to Present Updated Clinical Data from PKR Activator AG-348 at EHA - GlobeNewswire (press release) - May 18 at 3:23 PM logoBRIEF-Agios Pharmaceuticals to present updated clinical data from PKR activator AG-348 - May 18 at 12:01 PM logoThermo Fisher Scientific Signs Development Agreement with Agios ... - May 18 at 12:01 PM logoCelgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract - May 17 at 8:44 PM logoAgios to Present New Clinical Data from its IDH Programs at ASCO - May 17 at 8:44 PM logoAgios Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AGIO-US : May 15, 2017 - May 15 at 3:22 PM logoETFs with exposure to Agios Pharmaceuticals, Inc. : May 8, 2017 - May 8 at 8:56 PM logoAgios Pharmaceuticals Inc (AGIO) Receives Consensus Recommendation of "Buy" from Analysts - May 8 at 11:34 AM logoAgios Pharmaceuticals Inc (AGIO) Given a $90.00 Price Target at Canaccord Genuity - May 7 at 7:42 AM logoAgios Pharmaceuticals, Inc. 2017 Q1 - Results - Earnings Call Slides - May 5 at 8:24 PM logoAgios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus - Nasdaq - May 5 at 3:24 PM logoAgios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus - May 5 at 3:24 PM logoAgios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 - May 5 at 3:24 PM logoEdited Transcript of AGIO earnings conference call or presentation 4-May-17 12:00pm GMT - May 5 at 3:24 PM logoAgios Pharmaceuticals' (AGIO) CEO David Schenkein on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - May 5 at 1:30 AM logoAgios (AGIO) Q1 Loss Narrower than Expected; Sales Down Y/Y - Yahoo Finance - May 4 at 8:28 PM logoAgios Pharmaceuticals Inc (AGIO) Announces Earnings Results - May 4 at 4:56 PM logoAgios Pharmaceuticals (AGIO) Given Daily Coverage Optimism Rating of 0.04 - May 4 at 3:52 PM logoAgios Reports First Quarter 2017 Financial Results - GlobeNewswire (press release) - May 4 at 3:27 PM logoAgios Reports First Quarter 2017 Financial Results - May 4 at 3:27 PM logoInvestor Network: Agios Pharmaceuticals, Inc. to Host Earnings Call - May 4 at 3:27 PM logoAgios Pharmaceuticals reports 1Q loss - May 4 at 3:27 PM logoAgios (AGIO) Q1 Loss Narrower than Expected; Sales Down Y/Y - May 4 at 3:27 PM logoZacks: Brokerages Expect Agios Pharmaceuticals Inc (AGIO) Will Announce Quarterly Sales of $10.03 Million - May 4 at 2:24 PM logo[$$] Four Small Biotechs See Bullish April Stock Buys - May 3 at 7:20 AM logoInsider Selling: Agios Pharmaceuticals Inc (AGIO) CEO Sells 3,000 Shares of Stock - May 2 at 9:56 PM logoAgios Pharmaceuticals Inc (AGIO) Expected to Announce Earnings of -$1.78 Per Share - May 2 at 7:40 AM logoAgios Pharmaceuticals Inc (AGIO) Set to Announce Quarterly Earnings on Thursday - May 2 at 7:28 AM logoAgios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store? - Yahoo Finance - May 2 at 6:30 AM logoAgios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store? - May 1 at 3:24 PM logoAgios Pharmaceuticals (AGIO) Getting Somewhat Critical News Coverage, Report Finds - May 1 at 11:40 AM logoBRIEF-Agios announces closing of over-allotment option in public offering - April 30 at 4:41 PM logoAgios Announces Closing of Over-Allotment Option in Public ... - GlobeNewswire (press release) - April 28 at 9:01 PM logoAgios Announces Closing of Over-Allotment Option in Public Offering - April 28 at 9:01 PM logoBRIEF-Agios and Aurigene enter into license agreement for novel small molecules for cancer metabolism target - April 28 at 4:01 PM logoAgios to Webcast Conference Call of First Quarter 2017 Financial Results on May 4, 2017 - April 28 at 4:01 PM logoAgios Pharmaceuticals Inc (AGIO) Rating Increased to Hold at Zacks Investment Research - April 28 at 1:06 PM logoAgios Pharmaceuticals Inc (AGIO) to Post Q2 2017 Earnings of ($1.80) Per Share, Oppenheimer Holdings Forecasts - April 28 at 11:20 AM logoAgios Pharmaceuticals (AGIO) Given Daily News Impact Score of 0.26 - April 28 at 11:01 AM logoAgios Announces Exercise of Over-Allotment Option in Public ... - GlobeNewswire (press release) - April 26 at 3:36 PM logoAgios Announces Exercise of Over-Allotment Option in Public Offering - April 26 at 3:36 PM logoThe 1 Stock I'd Buy Right Now - April 26 at 3:36 PM logoCommit To Buy Agios Pharmaceuticals At $35, Earn 9.4% Annualized Using Options - Nasdaq - April 25 at 3:22 PM logoAgios Pharmaceuticals (AGIO) Getting Somewhat Negative News Coverage, Study Shows - April 25 at 2:30 PM logoAgios Announces Closing of Public Offering - April 25 at 8:16 AM



Agios Pharmaceuticals (AGIO) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff